Pituitary Adenoma Treatment

A pituitary adenoma is a tumor—usually benign—that develops in the pituitary, a small gland at the base of the brain that helps regulate many of the body’s hormones. Some pituitary adenomas produce excess hormones (functioning adenomas), while others do not (nonfunctioning adenomas). However, even a nonfunctioning pituitary adenoma can cause problems if it grows large enough to press on nearby structures, such as the optic nerves.

The primary goal of treating pituitary adenoma is to control tumor growth, normalize hormone production when necessary and preserve important neurologic functions, such as vision. Because pituitary adenomas can vary widely in size, hormone activity and growth rate, treatment is individualized to address each patient’s unique diagnosis, symptoms and overall health.

The specialists in the Endocrine Program at Moffitt Cancer Center provide comprehensive care for patients with functioning and nonfunctioning pituitary adenomas. Complex cases are reviewed by a multispecialty tumor board that includes neurosurgeons, endocrinologists, medical oncologists, radiation oncologists, neuroradiologists, neuropathologists, ophthalmologists and other specialists. Together, these experts evaluate the tumor’s size, location, hormone activity, imaging findings and other diagnostic information to tailor a treatment plan to its clinical and biologic characteristics and the patient’s individual needs. 

Active surveillance for pituitary adenoma

Not every pituitary adenoma requires immediate treatment. For many patients with a nonfunctioning microadenoma—a pituitary tumor that measures less than 10 millimeters across—or an incidentally discovered pituitary tumor that is not causing symptoms, active surveillance may be the preferred initial approach. Rather than exposing the patient to unnecessary treatment, the healthcare team will carefully monitor the tumor for signs of growth or changes in hormone production.

Because many pituitary adenomas grow slowly or may not grow at all, active surveillance can allow the healthcare team to intervene if the tumor begins to affect pituitary function, vision or other nearby structures.

Even if the tumors in your pituitary gland or adrenal gland are not cancer by definition, they are doing something else. They are making excess hormones, or they're in a location where they may be big enough to be detrimental to critical structures.

Prerna Dogra, MD

When is observation appropriate for pituitary adenoma?

A “watch-and-wait” approach may be appropriate for a patient whose pituitary adenoma:

• Is small, such as a microadenoma
• Does not produce excess hormones or cause hormone deficiencies that require treatment
• Is not compressing the optic nerves, optic chiasm or other nearby structures
• Is not causing significant vision changes or other neurologic symptoms
• Appears stable on imaging studies

Additionally, active surveillance may be recommended for certain older adults and patients with other medical conditions when the potential risks of treatment outweigh the benefits of immediate intervention. The decision to observe rather than treat is individualized based on the patient’s symptoms, tumor characteristics, age, overall health and personal preferences.

What does active surveillance for pituitary adenoma involve?

A patient undergoing active surveillance will be evaluated on a regular schedule to determine whether the tumor remains stable or treatment has become necessary. Monitoring may include:

• Periodic magnetic resonance imaging (MRI) scans to evaluate the tumor’s size, growth pattern and relationship to nearby structures, such as the optic nerves and optic chiasm
• Hormone testing to monitor pituitary function and detect changes in hormone production or new pituitary hormone deficiencies
• Vision testing to identify subtle changes in visual acuity or peripheral vision that may occur if the tumor begins to compress the optic pathways
• Neurologic and endocrine evaluations to assess for new symptoms, such as headaches, fatigue, menstrual changes, sexual dysfunction, unexplained weight changes or other signs of hormonal imbalance

If follow-up testing shows that the adenoma is enlarging, producing excess hormones, causing pituitary dysfunction or compressing nearby structures, the healthcare team may recommend transitioning from active surveillance to treatment. Depending on the patient’s diagnosis, treatment may involve surgery, medical therapy, radiation therapy or a combination of approaches to achieve long-term tumor control and preserve neurologic and endocrine function.

Surgery for pituitary adenoma

Surgery is an important treatment option for many pituitary adenomas, particularly when the tumor is causing symptoms or affecting nearby structures. At Moffitt, our neurosurgeons work closely with endocrinologists, medical oncologists, radiation oncologists, neuroradiologists, neuropathologists, ophthalmologists and other specialists to determine whether surgery is appropriate and, if so, coordinate care before, during and after the procedure.

Whenever possible, Moffitt’s surgeons use minimally invasive techniques to remove pituitary tumors while limiting disruption to surrounding healthy tissues. Endoscopic endonasal surgery, which is performed through the nasal passages without external incisions, is commonly used to treat pituitary adenoma. Specialized endoscopic instruments provide direct access to the pituitary region with excellent visualization and precision.

When is surgery a treatment option for pituitary adenoma?

Surgery may be recommended if a pituitary adenoma is pressing on nearby structures, causing certain types of excess hormone production or continuing to grow despite other treatments. The decision depends on the type, size and location of the tumor as well as the patient’s symptoms and overall health.

Surgery may be appropriate for a patient whose pituitary adenoma:

• Causes vision loss, double vision or peripheral vision changes due to compression of the optic nerves or optic chiasm
• Produces excess growth hormone, adrenocorticotropic hormone (ACTH) or thyroid-stimulating hormone (TSH) and can be safely removed
• Continues to enlarge during active surveillance
• Causes significant headaches or other neurologic symptoms related to its size or location
• Compresses normal pituitary tissue, contributing to hormone deficiencies
• Persists or progresses despite appropriate medical therapy
• Has features that suggest more aggressive behavior

The primary goals of surgery are to remove as much of the tumor as safely possible, relieve pressure on nearby structures, normalize excess hormone production when feasible and preserve normal pituitary function.

What are the different types of pituitary adenoma surgery?

The optimal surgical approach depends on the tumor’s size, location, growth pattern and relationship to surrounding structures. Most pituitary adenomas that require surgery can be approached using minimally invasive techniques, although a larger or more complex tumor may require an alternative approach.

Endoscopic endonasal transsphenoidal surgery

Endoscopic endonasal transsphenoidal surgery is the most commonly used surgical approach for removing a pituitary adenoma. During this minimally invasive procedure, the neurosurgeon will insert a thin endoscope and specialized surgical instruments through the nostrils to reach the pituitary gland without making an external incision.

The endoscope will provide a magnified, high-definition view of the surgical field, allowing the surgeon to remove as much of the tumor as safely possible while preserving nearby nerves, blood vessels and normal pituitary tissue. Because no facial incisions are required, the patient may experience less discomfort and a faster recovery than with traditional open surgery.

Microscopic transsphenoidal surgery

Like endoscopic endonasal transsphenoidal surgery, microscopic transsphenoidal surgery accesses the pituitary gland through the nasal passages. This technique uses an operating microscope rather than an endoscope to visualize the tumor.

Although endoscopic techniques are widely used for pituitary adenoma treatment, microscopic transsphenoidal surgery remains an effective option in select cases depending on the patient’s anatomy, tumor characteristics and the surgeon’s clinical judgment.

Craniotomy

A craniotomy involves temporarily removing a portion of the skull to access the brain and pituitary region. This approach is rarely necessary for pituitary adenoma but may be considered if the tumor is exceptionally large, extends into an area that cannot be safely reached through a transsphenoidal approach or involves critical blood vessels, nerves or other surrounding structures.

Because a craniotomy is a more extensive operation than transsphenoidal surgery, recovery is generally longer. However, for a complex tumor, it may provide the safest surgical access while allowing the neurosurgeon to protect surrounding brain structures.

What are the risks and possible side effects of surgery for pituitary adenoma?

The potential risks and side effects of pituitary adenoma surgery depend on the size and location of the tumor and the type of procedure performed. The surgical team will carefully monitor the patient throughout recovery and provide individualized care to reduce the risk of complications. Potential side effects include:

• Temporary nasal congestion or discomfort – Many patients who undergo transsphenoidal surgery experience nasal congestion, mild drainage or sinus pressure for several weeks. Using a saline nasal spray as directed and following postoperative nasal care instructions can help promote healing.
• Headache or postoperative pain – Mild to moderate discomfort that occurs after pituitary adenoma surgery can usually be managed with pain medication, adequate rest and gradual resumption of normal activities.
• Hormone deficiencies – Surgery may temporarily or permanently affect normal pituitary hormone production. Periodic blood tests can help identify deficiencies early, and hormone replacement therapy may be prescribed if needed.
• Arginine vasopressin deficiency (AVP-D) – Formerly called diabetes insipidus, AVP-D can cause excessive thirst and frequent urination if surgery temporarily or permanently disrupts the body’s regulation of water balance. Careful monitoring of fluid and sodium levels and medication when needed can help manage the condition.
• Cerebrospinal fluid (CSF) leak – Leakage of the fluid surrounding the brain is uncommon but can occur after transsphenoidal surgery. The patient should promptly report any clear, watery drainage from the nose, particularly if it is persistent, as well as severe headache or fever so the healthcare team can evaluate these symptoms.
• Vision changes – Vision may improve after surgery when a pituitary adenoma has been compressing the optic pathways. New or worsening vision changes are uncommon but should be reported immediately for evaluation.
• Bleeding or infection – As with any operation, bleeding or infection is possible. Following postoperative care instructions and promptly reporting fever, increasing pain or other concerning symptoms can help the healthcare team identify and manage complications early.
• Changes in sodium levels – Some patients develop low blood sodium several days after surgery, which can cause headache, nausea, fatigue or confusion. Following the healthcare team’s instructions about fluid intake and completing scheduled blood tests can help detect and address sodium changes promptly.

What is the recovery process like after surgery for pituitary adenoma?

Most patients remain in the hospital for one to three days after endoscopic or microscopic transsphenoidal surgery, although the length of stay can vary depending on the extent of the procedure and the patient’s overall health. Recovery after a craniotomy is typically longer and may require several additional days in the hospital.

During the early recovery period, the healthcare team will closely monitor the patient’s hormone levels, sodium levels, fluid balance, neurologic function and vision. The patient will typically be advised to avoid heavy lifting, strenuous exercise, nose blowing and other activities that can increase pressure within the nasal passages for several weeks while healing occurs.

Many patients gradually resume light daily activities within one to two weeks after uncomplicated transsphenoidal surgery and return to work and other routine activities within several weeks, depending on how they feel and the nature of their activities. Nasal congestion, fatigue and other temporary effects may take several additional weeks to fully resolve. Recovery after a craniotomy generally takes longer.

Follow-up care typically includes MRI scans, hormone testing and endocrinology evaluations to assess the response to treatment and determine whether additional therapy is needed. Because pituitary function can change after surgery, some patients require temporary or long-term hormone replacement therapy.

Most patients do not require formal physical therapy after transsphenoidal surgery. However, those who experience prolonged weakness, balance problems or vision changes may benefit from rehabilitation or other supportive services as they return to their usual activities.

Florida's Top Choice for Cancer Care

Moffitt is Florida's top cancer hospital by expert opinion in America's Best Cancer Hospitals by U.S. News & World Report.

Schedule an Appointment

Medical therapy for pituitary adenoma

Medications are the first-line treatment for certain hormone-producing pituitary adenomas, particularly prolactinomas. Medical therapy can help normalize or control hormone levels, reduce tumor size when possible, relieve symptoms and prevent long-term complications associated with excess hormone production. For many patients with prolactinoma, medication can provide effective long-term control without the need for surgery.

The choice of medication depends on the type of hormone the adenoma produces as well as the patient’s symptoms, hormone levels and overall treatment goals. Endocrinologists will work closely with other members of the multispecialty team to monitor treatment response and adjust therapy as needed.

When is medical therapy used for pituitary adenoma?

Medical therapy may be used in several ways depending on the type of pituitary adenoma, the hormones it produces and the patient’s response to other treatments. Medication may be recommended:

• As the primary treatment for a prolactin-producing adenoma (prolactinoma)
• Before surgery to help control excess hormone production or, in certain cases, reduce tumor size
• After surgery if excess hormone production persists or residual tumor requires additional treatment
• If surgery is not appropriate due to the tumor’s characteristics or the patient’s overall health or personal preferences
• Along with radiation therapy to help control hormone production while the effects of radiation develop
• For a recurrent tumor that continues to produce excess hormones after previous treatment

Which medications are most effective for pituitary adenoma?

Several classes of medication can be used to treat specific types of hormone-producing pituitary adenomas. The appropriate medication depends primarily on which hormone is being produced in excess and whether the patient has received other treatments. Common options include:

• Dopamine agonists (cabergoline and bromocriptine) – These medications are the preferred first-line treatment for prolactinomas. They can lower prolactin levels and often shrink the tumor, potentially allowing the patient to achieve long-term control without surgery.
• Somatostatin analogs (octreotide and lanreotide) – These medications can reduce growth hormone production and are commonly used to treat acromegaly when surgery does not fully normalize hormone levels or is not appropriate.
• Pasireotide – This somatostatin analog may be used to treat certain patients with acromegaly or Cushing disease when other treatments have not provided adequate hormone control.
• Growth hormone receptor antagonist (pegvisomant) – Pegvisomant blocks the effects of excess growth hormone and may be used to treat acromegaly when hormone levels remain elevated despite surgery or other medications.
• Steroidogenesis inhibitors – Medications such as osilodrostat, ketoconazole, levoketoconazole and metyrapone can reduce the amount of cortisol produced by the adrenal glands. They may be used to control excess cortisol in patients with Cushing disease if surgery has not achieved remission, while awaiting the effects of another treatment or if surgery is not appropriate.
• Other hormone-directed therapies – Depending on the specific tumor subtype and response to treatment, additional medications may be used alone or in combination to control excess hormone activity and relieve symptoms.

What are the risks and possible side effects of medical therapy for pituitary adenoma?

Side effects of medical therapy can vary according to the medication prescribed and the hormone disorder being treated. The healthcare team will carefully monitor the patient with regular office visits, blood tests and, when appropriate, imaging studies to ensure treatment remains safe and effective.

Potential side effects include:

• Nausea, dizziness or low blood pressure (dopamine agonists) – These symptoms often improve as the body adjusts to treatment. Taking medication with food or at bedtime, when appropriate, and rising slowly from a sitting or lying position can help minimize discomfort.
• Headache or gastrointestinal symptoms (somatostatin analogs) – Headache, abdominal discomfort, diarrhea or bloating may occur, particularly when treatment begins. Eating smaller meals and maintaining good hydration can help relieve symptoms.
• Gallstones (somatostatin analogs) – Long-term treatment can increase the risk of gallstone formation. Periodic monitoring and prompt reporting of persistent or severe abdominal pain can help the healthcare team identify problems early.
• Elevated blood sugar (particularly pasireotide) – Pasireotide can increase blood glucose levels and, in some patients, contribute to diabetes. Regular glucose monitoring and adjustments to diet or diabetes medications when needed can help maintain healthy blood sugar levels.
• Injection-site reactions (injectable medications) – Any mild redness, swelling or soreness at the injection site will usually resolve within a few days. Following administration instructions and rotating injection sites when applicable can help reduce irritation.
• Liver function changes (pegvisomant and certain steroidogenesis inhibitors) – Some medications can affect liver function. Regular blood tests can allow the healthcare team to monitor for changes, and the patient should promptly report symptoms such as yellowing of the skin or eyes, dark urine or persistent fatigue.
• Cortisol levels becoming too low (steroidogenesis inhibitors) – Medications used for Cushing disease can sometimes reduce cortisol below the desired level, potentially causing fatigue, weakness, nausea, dizziness or low blood pressure. Regular cortisol testing and medication adjustments can help prevent or manage this complication.

Radiation therapy for pituitary adenoma

Radiation therapy uses highly focused, high-energy radiation to damage tumor cells and prevent them from growing or dividing. For pituitary adenoma, radiation therapy is typically reserved for residual or recurrent tumors or for cases in which tumor growth or excess hormone production cannot be adequately controlled with surgery, medication or a combination of treatments.

At Moffitt, our radiation oncologists collaborate closely with medical physicists, dosimetrists and the broader multispecialty team to develop highly precise radiation treatment plans. Advanced treatment planning and delivery techniques can allow the team to target the pituitary adenoma while minimizing radiation exposure to nearby healthy structures, including the optic nerves, optic chiasm, brain tissue and normal pituitary gland tissue.

How does radiation therapy treat pituitary adenoma?

Radiation therapy is most commonly used to control a residual or recurrent pituitary adenoma after surgery or to reduce excess hormone production when other treatments have not provided adequate control. Because pituitary adenomas are typically slow-growing tumors, the effects of radiation therapy often develop gradually over months to several years.

Radiation therapy may be recommended to:

• Control residual tumor after surgery when complete removal was not possible or safe
• Treat a pituitary adenoma that has returned or progressed after previous treatment
• Reduce hormone secretion from a functioning adenoma that remains active despite surgery or medical therapy
• Stabilize a tumor that cannot be safely removed because of its proximity to critical nerves, blood vessels or other structures
• Provide long-term tumor control when additional surgery is not appropriate

What radiation treatment techniques are available for pituitary adenoma?

The radiation delivery technique selected will depend on the tumor’s size, location and proximity to sensitive structures, such as the optic nerves and optic chiasm. The healthcare team will carefully evaluate the patient’s anatomy and treatment goals to recommend the safest and most effective approach. Techniques include:

Stereotactic radiosurgery (SRS)

Despite its name, stereotactic radiosurgery does not involve an operation. Instead, SRS delivers a highly concentrated dose of radiation to the pituitary adenoma during a single treatment session.

Using detailed MRI and CT imaging, the treatment team can precisely target the tumor while limiting radiation exposure to nearby healthy tissues. SRS may be appropriate for a small residual or recurrent pituitary adenoma that is located a safe distance from the optic nerves and optic chiasm.

Fractionated stereotactic radiation therapy (FSRT)

FSRT delivers the total radiation dose in smaller amounts over multiple treatment sessions. Dividing the dose into fractions allows surrounding healthy tissues time to recover between treatments while providing effective long-term tumor control.

Fractionated stereotactic radiation therapy may be particularly appropriate for a large pituitary adenoma or a tumor located close to the optic nerves, optic chiasm or other sensitive structures that could be exposed to too much radiation during a single SRS treatment.

Intensity-modulated radiation therapy (IMRT)

IMRT uses sophisticated computer planning to shape the radiation beams to closely conform to the tumor. By varying the intensity of the radiation within each beam, this approach can deliver the prescribed dose to an irregularly shaped treatment area while reducing exposure to nearby healthy tissues.

Intensity-modulated radiation therapy may be appropriate for a pituitary adenoma with a complex shape or location that requires especially precise radiation dose distribution around critical structures.

What are the possible side effects of radiation therapy for pituitary adenoma?

Most patients tolerate radiation therapy well. Side effects can vary depending on the treatment technique, radiation dose and location of the tumor. The healthcare team will monitor the patient closely throughout treatment and provide supportive care to minimize any discomfort and address concerns as early as possible. Potential side effects include:

• Fatigue during treatment – Mild to moderate tiredness may develop over the course of fractionated radiation therapy or shortly after treatment. Prioritizing adequate rest, maintaining light physical activity and eating a balanced diet can help support energy levels.
• Temporary skin irritation or hair thinning – Depending on the radiation delivery technique and treatment area, the patient may experience mild skin redness or temporary hair thinning where radiation passes through the scalp. Using gentle skin care products and following the healthcare team’s recommendations can help protect sensitive skin.
• Headache or temporary inflammation – Some patients experience headaches or temporary swelling around the treated area during or shortly after radiation therapy. These symptoms can often be managed with medications recommended by the healthcare team, including corticosteroids when appropriate.
• Pituitary hormone deficiencies (hypopituitarism) – Radiation therapy can gradually reduce normal pituitary hormone production months or years after treatment. Lifelong endocrine follow-up and periodic hormone testing can identify deficiencies early so hormone replacement therapy can be started if needed.
• Vision changes (uncommon) – Modern radiation treatment planning carefully limits the dose delivered to the optic nerves and optic chiasm, making serious vision problems uncommon. The patient should promptly report any new or worsening visual symptoms for evaluation.
• Rare long-term effects on surrounding brain tissue – Highly precise treatment planning can minimize radiation exposure to healthy brain tissue, but delayed effects may still occur. Long-term clinical follow-up and imaging when appropriate can help identify and manage these side effects.

What is the radiation therapy schedule for pituitary adenoma, and what is the recovery process like?

The treatment schedule can vary depending on the type of radiation therapy used. Stereotactic radiosurgery is typically completed in a single treatment session. When delivering the radiation dose over multiple sessions is safer or more appropriate, stereotactic radiation therapy may be given in several fractions. Fractionated stereotactic radiation therapy and IMRT may be delivered once a day, five days per week, for approximately four to six weeks.

Radiation therapy is performed on an outpatient basis, allowing most patients to continue many of their normal daily activities throughout treatment. Fatigue may develop gradually during fractionated treatment and can be most noticeable toward the end of therapy or shortly afterward before gradually improving over the following weeks. Recovery after a single SRS treatment is generally faster, although individual experiences vary.

Because the effects of radiation therapy on pituitary adenoma develop gradually, follow-up will continue long after treatment is completed. MRI scans and hormone testing may be performed periodically for several years to evaluate tumor control, determine whether excess hormone production is improving and monitor pituitary function.

Targeted therapy and chemotherapy for aggressive pituitary adenoma

Most pituitary adenomas can be successfully managed with active surveillance, surgery, medical therapy, radiation therapy or a combination of these approaches. However, a small number of tumors may demonstrate aggressive behavior, continuing to grow despite standard treatments. In these uncommon situations, Moffitt’s multispecialty team may consider systemic treatments such as chemotherapy or, in highly select cases, targeted therapy or immunotherapy.

Treatment decisions are based on the tumor’s clinical behavior, pathology, previous response to therapy and, when appropriate, molecular characteristics. For tumors that continue to progress despite standard treatment, molecular profiling can help identify biologic features that may inform additional treatment options or eligibility for a clinical trial.

When is chemotherapy used for aggressive pituitary adenoma?

Chemotherapy is rarely necessary for pituitary adenoma. However, it may be recommended for an aggressive pituitary tumor that continues to progress despite standard treatments, such as surgery, radiation therapy and appropriate hormone-directed medical therapy.

Temozolomide is the recommended first-line chemotherapy for aggressive pituitary tumors and pituitary carcinomas that demonstrate continued progression after previous multimodal treatment. This oral chemotherapy drug can damage tumor cell DNA, interfering with the cells’ ability to survive and reproduce. Treatment response is generally evaluated after the first three cycles to determine whether the medication is controlling the tumor.

For a rapidly progressing tumor that cannot be safely removed with additional surgery, temozolomide may sometimes be administered along with radiation therapy. This approach is considered on an individual basis by Moffitt’s multispecialty team because evidence supporting combined treatment in pituitary tumors remains limited.

When are targeted therapy and immunotherapy used for aggressive pituitary adenoma?

Targeted therapy and immunotherapy are not standard treatments for most pituitary adenomas. However, these approaches may be considered for an exceptionally aggressive or treatment-resistant tumor, particularly after progression on temozolomide, when molecular testing identifies a potentially actionable tumor characteristic or a clinical trial is available.

Targeted therapies are designed to interfere with specific molecules or signaling pathways involved in tumor growth. Because no single molecular target routinely determines treatment for pituitary adenoma, these therapies are generally considered on a case-by-case basis or through clinical trials.

Immune checkpoint inhibitors can help the immune system recognize and attack tumor cells. Current guidelines suggest considering checkpoint inhibitors for selected patients with pituitary carcinoma that progresses rapidly after temozolomide, particularly when molecular testing identifies features associated with potential immunotherapy benefit, such as mismatch repair deficiency or a high tumor mutational burden.

Which biomarkers are tested before targeted therapy is considered for pituitary adenoma?

Unlike some other solid tumors, pituitary adenomas are not routinely treated according to mutations in genes such as EGFR, KRAS or BRAF. Molecular testing is generally reserved for aggressive or treatment-resistant tumors when the results could help guide subsequent therapy or identify an appropriate clinical trial.

Depending on the clinical situation, testing may evaluate:

• Mismatch repair (MMR) proteins and microsatellite instability (MSI) – Deficient DNA mismatch repair may help identify a tumor that could potentially respond to an immune checkpoint inhibitor.
• Tumor mutational burden (TMB) – A high number of tumor mutations may provide additional support for considering immunotherapy in selected patients with advanced disease.
• MGMT expression – MGMT is a DNA repair protein that can counteract the effects of temozolomide. Lower MGMT expression has been associated with a greater likelihood of response in some studies, while high expression has been associated with treatment resistance. However, MGMT is not a definitive predictor, and current guidelines do not recommend using it routinely to determine whether a patient should receive an initial trial of temozolomide.
• Other molecular alterations – Comprehensive genomic profiling may reveal uncommon alterations or signaling pathways that could support the use of an investigational targeted therapy or eligibility for a clinical trial.

What are the possible side effects of chemotherapy for aggressive pituitary adenoma?

Because temozolomide is the primary chemotherapy used for aggressive pituitary tumors, its potential side effects are the most relevant to discuss. Many side effects can be managed with supportive care or adjustments to the treatment schedule.

Potential side effects include:

• Fatigue – Reduced energy is one of the more common effects of temozolomide. Balancing activity with adequate rest and maintaining good nutrition can help the patient manage fatigue during treatment.
• Nausea or vomiting – Antinausea medications can be given with temozolomide to prevent or reduce these symptoms. The patient should tell the healthcare team if nausea interferes with eating, drinking or taking medication.
• Low blood cell counts – Temozolomide can temporarily reduce white blood cells and platelets, potentially increasing the risk of infection or bleeding. Regular blood tests allow the treatment team to monitor blood counts and adjust or delay treatment when necessary.
• Liver function changes – Blood tests will be performed periodically to monitor liver function. The patient should promptly report symptoms such as yellowing of the skin or eyes, dark urine or unusual fatigue.

What are the possible side effects of immunotherapy for pituitary adenoma?

Unlike chemotherapy, immunotherapy stimulates the immune system to recognize and attack tumor cells. As a result, its side effects can occur when activated immune cells cause inflammation in healthy organs and tissues.

Although immunotherapy is used only in exceptional cases of aggressive pituitary tumors or pituitary carcinoma, potential immune-related side effects include:

• Skin inflammation – Rash or itching may occur during treatment. Using recommended moisturizers and topical medications and reporting new skin changes promptly can help manage symptoms.
• Colitis – Inflammation of the colon can cause diarrhea and abdominal pain. Reporting these symptoms early can allow the healthcare team to provide treatment before inflammation becomes more severe.
• Pneumonitis – Inflammation of the lungs may cause coughing or shortness of breath. New or worsening respiratory symptoms should be reported promptly for evaluation.
• Endocrine inflammation – Immunotherapy can affect the thyroid, adrenal glands or pituitary gland, resulting in hormone deficiencies. Routine laboratory testing can identify these changes, and hormone replacement therapy may be prescribed if needed.
• Hepatitis – Liver inflammation may initially cause few noticeable symptoms, making routine blood tests important. Yellowing of the skin or eyes, dark urine or persistent fatigue should be reported promptly.
• Infusion reactions – Fever, chills or flushing can occasionally occur during intravenous treatment. Careful monitoring during the infusion allows the healthcare team to manage a reaction if one develops.

Pituitary adenoma clinical trials at Moffitt Cancer Center

Clinical trials play an important role in advancing the treatment of pituitary adenomas, particularly for patients with aggressive, recurrent or treatment-resistant tumors. Through these carefully designed research studies, scientists can evaluate promising medications, precision medicine strategies, advanced radiation delivery techniques and other innovative approaches that may improve tumor control, hormone management and quality of life.

As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Moffitt is at the forefront of cancer and endocrine tumor research. Eligible patients may have opportunities to participate in clinical trials evaluating new treatment approaches based on their diagnosis and other eligibility criteria. Every clinical trial follows rigorous scientific and ethical standards, and participation is always voluntary.

Why should a patient consider a clinical trial for pituitary adenoma?

For some patients, participating in a clinical trial can provide access to promising therapies before those options become widely available in other treatment settings. Depending on the patient’s diagnosis and the studies currently available, investigational approaches may include novel targeted therapies, emerging hormone-directed medications, precision medicine strategies or other treatments for aggressive or treatment-resistant tumors.

Clinical trials also help researchers answer important questions that can shape future standards of care. The specialists in Moffitt’s Endocrine Program can evaluate whether an appropriate clinical trial is available and discuss investigational options alongside established treatments, helping each patient make an informed decision about their care.

Why choose Moffitt Cancer Center for pituitary adenoma treatment

Pituitary adenomas require highly specialized care because these tumors can affect hormone production, vision, neurologic function and many other aspects of health. At Moffitt, patients can benefit from a multispecialty approach that brings together neurosurgeons, endocrinologists, medical oncologists, radiation oncologists, neuroradiologists, neuropathologists, ophthalmologists and other specialists with expertise relevant to pituitary tumors.

By combining advanced imaging, sophisticated surgical techniques, precision radiation therapy, individualized medical management and access to innovative clinical research, Moffitt develops a comprehensive treatment plan tailored to each patient’s diagnosis and treatment goals. Our collaborative approach allows multiple specialists to evaluate complex cases and determine how to achieve effective tumor control while preserving pituitary, neurologic and visual function whenever possible.

If you would like to learn more about pituitary adenoma treatment, you can request an appointment with a specialist in the Endocrine Program at Moffitt by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.